Castle Biosciences
CSTL
32.86
-0.55
-1.63%
Castle Biosciences
US · CSTL
#3242 by market cap
Listed 2019
32.86
-0.55
-1.63%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/3/3
-
Rating change
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $52Market Newswire · 2026/5/7
-
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q3 Adjusted Loss $0.13 per Share, Vs. FactSet Est of $-0.32MT Newswires · 2026/11/6
-
Canadian Investment Regulatory Organization Trading Halt - CSTL.PPR Newswire · 2026/11/10
-
Rating change
Mizuho Securities Initiates Castle Biosciences(CSTL.US) With Buy Rating, Announces Target Price $60Market Newswire · 2026/10/29
-
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $52Market Newswire · 2026/11/10
-
A Quick Look at Today's Ratings for Castle Biosciences(CSTL.US), With a Forecast Between $39 to $50Market Newswire · 2026/11/7
-
Rating change
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/4/20
-
KeyBanc Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/11/6
-
Rating change
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/5/13
-
Rating change
Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $36Market Newswire · 2026/7/31
-
Rating change
Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $43Market Newswire · 2026/5/7
-
Rating change
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $57Market Newswire · 2026/10/1
-
Rating change
KeyBanc Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $35Market Newswire · 2026/5/29
-
Rating change
Guggenheim Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $47Market Newswire · 2026/5/7
-
Rating change
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/8/3
-
Rating change
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $57Market Newswire · 2026/7/31
-
Rating change
Roth MKM Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $50Market Newswire · 2026/9/22
-
Rating change
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/5/13
-
Rating change
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44Market Newswire · 2026/8/3
-
Rating change
Guggenheim Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $47Market Newswire · 2026/1/26
-
Rating change
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $52Market Newswire · 2026/1/14
-
Rating change
KeyBanc Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $50Market Newswire · 2026/1/30
-
Rating change
Guggenheim Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $43Market Newswire · 2026/1/5
-
Rating change
Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44Market Newswire · 2026/2/27
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Castle Biosciences discussion 0 comments